Eyetech, Inc.
http://www.eyetech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyetech, Inc.
Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings
More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.
Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.
NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.
Royalty Rights To AMD Drug Spur $175 Million Capital Raise For Ophthotech
Money will finance 1,900-patient, 200-site Phase III trial for wet AMD drug Fovista, expected to work in concert with anti-VEGF therapies such as Lucentis to restore eye function. The transaction is just the latest ophthalmology financing involving Novo AS, SV Life Sciences and executives once with Eyetech.